310 related articles for article (PubMed ID: 31707825)
1. Randomized Study of Providing Evidence Context to Mitigate Physician Misinterpretation Arising From Off-Label Drug Promotion.
Schwartz LM; Woloshin S; Lu Z; Ross KM; Tessema FA; Peter D; Kesselheim AS
Circ Cardiovasc Qual Outcomes; 2019 Nov; 12(11):e006073. PubMed ID: 31707825
[TBL] [Abstract][Full Text] [Related]
2. Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications.
Bays HE; Tighe AP; Sadovsky R; Davidson MH
Expert Rev Cardiovasc Ther; 2008 Mar; 6(3):391-409. PubMed ID: 18327998
[TBL] [Abstract][Full Text] [Related]
3. U.S. physician knowledge of the FDA-approved indications and evidence base for commonly prescribed drugs: results of a national survey.
Chen DT; Wynia MK; Moloney RM; Alexander GC
Pharmacoepidemiol Drug Saf; 2009 Nov; 18(11):1094-100. PubMed ID: 19697444
[TBL] [Abstract][Full Text] [Related]
4. Influence of data disclosures on physician decisions about off-label uses: findings from a qualitative study.
Chansky MC; Price SM; Aikin KJ; O'Donoghue AC
BMC Prim Care; 2022 Apr; 23(1):87. PubMed ID: 35439962
[TBL] [Abstract][Full Text] [Related]
5. Lowering triglycerides to modify cardiovascular risk: will icosapent deliver?
Scherer DJ; Nicholls SJ
Vasc Health Risk Manag; 2015; 11():203-9. PubMed ID: 25848301
[TBL] [Abstract][Full Text] [Related]
6. Drugs for hypertriglyceridemia.
Med Lett Drugs Ther; 2013 Mar; 55(1411):17-9. PubMed ID: 23467119
[No Abstract] [Full Text] [Related]
7. Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association.
Skulas-Ray AC; Wilson PWF; Harris WS; Brinton EA; Kris-Etherton PM; Richter CK; Jacobson TA; Engler MB; Miller M; Robinson JG; Blum CB; Rodriguez-Leyva D; de Ferranti SD; Welty FK;
Circulation; 2019 Sep; 140(12):e673-e691. PubMed ID: 31422671
[TBL] [Abstract][Full Text] [Related]
8. Off-label indications for antidepressants in primary care: descriptive study of prescriptions from an indication based electronic prescribing system.
Wong J; Motulsky A; Abrahamowicz M; Eguale T; Buckeridge DL; Tamblyn R
BMJ; 2017 Feb; 356():j603. PubMed ID: 28228380
[No Abstract] [Full Text] [Related]
9. Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia.
Wohl DA; Tien HC; Busby M; Cunningham C; Macintosh B; Napravnik S; Danan E; Donovan K; Hossenipour M; Simpson RJ
Clin Infect Dis; 2005 Nov; 41(10):1498-504. PubMed ID: 16231263
[TBL] [Abstract][Full Text] [Related]
10. Omega-3 carboxylic acids monotherapy and combination with statins in the management of dyslipidemia.
Benes LB; Bassi NS; Davidson MH
Vasc Health Risk Manag; 2016; 12():481-490. PubMed ID: 28003756
[TBL] [Abstract][Full Text] [Related]
11. The Law and Practice of Off-Label Prescribing and Physician Promotion.
Syed SA; Dixson BA; Constantino E; Regan J
J Am Acad Psychiatry Law; 2021 Mar; 49(1):53-59. PubMed ID: 33234538
[TBL] [Abstract][Full Text] [Related]
12. Overview of prescription omega-3 fatty acid products for hypertriglyceridemia.
Weintraub HS
Postgrad Med; 2014 Nov; 126(7):7-18. PubMed ID: 25387209
[TBL] [Abstract][Full Text] [Related]
13. Physicians' Perspectives on FDA Approval Standards and Off-label Drug Marketing.
Kesselheim AS; Woloshin S; Lu Z; Tessema FA; Ross KM; Schwartz LM
JAMA Intern Med; 2019 May; 179(5):707-709. PubMed ID: 30667474
[TBL] [Abstract][Full Text] [Related]
14. Knowledge and perception of off-label drug use amongst prescribing physicians in a tertiary care hospital.
Kannan S; Bahl A; Khosla PP
Int J Risk Saf Med; 2015; 27(4):219-23. PubMed ID: 26756895
[TBL] [Abstract][Full Text] [Related]
15. Unwarranted claims of drug efficacy in pharmaceutical sales visits: are drugs approved on the basis of surrogate outcomes promoted appropriately?
Habibi R; Lexchin J; Mintzes B; Holbrook A
Br J Clin Pharmacol; 2017 Nov; 83(11):2549-2556. PubMed ID: 28664660
[TBL] [Abstract][Full Text] [Related]
16. Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia.
McKenney JM; Sica D
Pharmacotherapy; 2007 May; 27(5):715-28. PubMed ID: 17461707
[TBL] [Abstract][Full Text] [Related]
17. On-label and off-label prescribing patterns of erythropoiesis-stimulating agents in inpatient hospital settings in the US during the period of major regulatory changes.
Seetasith A; Holdford D; Shah A; Patterson J
Res Social Adm Pharm; 2017; 13(4):778-788. PubMed ID: 27595426
[TBL] [Abstract][Full Text] [Related]
18. Rationale for prescription omega-3-acid ethyl ester therapy for hypertriglyceridemia: a primer for clinicians.
Bays H
Drugs Today (Barc); 2008 Mar; 44(3):205-46. PubMed ID: 18536782
[TBL] [Abstract][Full Text] [Related]
19. Fish oil and the management of hypertriglyceridemia.
Mattar M; Obeid O
Nutr Health; 2009; 20(1):41-9. PubMed ID: 19326719
[TBL] [Abstract][Full Text] [Related]
20. Pharmaceutical Industry Off-label Promotion and Self-regulation: A Document Analysis of Off-label Promotion Rulings by the United Kingdom Prescription Medicines Code of Practice Authority 2003-2012.
Vilhelmsson A; Davis C; Mulinari S
PLoS Med; 2016 Jan; 13(1):e1001945. PubMed ID: 26812151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
